Test Per Rilievo Sars Cox 19 Su Superfici

Lab Reagents

Human IgG antibody Laboratories manufactures the test per rilievo sars cox 19 su superfici reagents distributed by Genprice. The Test Per Rilievo Sars Cox 19 Su Superfici reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Test products are available in stock. Specificity: Test Category: Per Group: Rilievo Sars

Rilievo Sars information

SARS-CoV-2 Antigen Rapid Test Kit
CoV2Ag-25 25T/kit
EUR 42
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection.

SARS-CoV-2 Rapid Antigen Test Nasal
9901-NCOV-03G 25 Tests/Kit
EUR 112.8
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

SU 5402
A3843-10 10 mg
EUR 170.4
Description: IC50: 0.02, 0.03, 0.51 and > 100 ?M for VEGFR2, FGFR1, PDGFR? and EGFR, respectivelySU 5402 is an inhibitor of VEGF, FGF, and PDGF receptor tyrosine kinases.

SU 5402
A3843-25 25 mg
EUR 296.4
Description: IC50: 0.02, 0.03, 0.51 and > 100 ?M for VEGFR2, FGFR1, PDGFR? and EGFR, respectivelySU 5402 is an inhibitor of VEGF, FGF, and PDGF receptor tyrosine kinases.

SU 5402
A3843-5.1 10 mM (in 1mL DMSO)
EUR 166.8
Description: IC50: 0.02, 0.03, 0.51 and > 100 ?M for VEGFR2, FGFR1, PDGFR? and EGFR, respectivelySU 5402 is an inhibitor of VEGF, FGF, and PDGF receptor tyrosine kinases.

SU 5402
A3843-50 50 mg
EUR 490.8
Description: IC50: 0.02, 0.03, 0.51 and > 100 ?M for VEGFR2, FGFR1, PDGFR? and EGFR, respectivelySU 5402 is an inhibitor of VEGF, FGF, and PDGF receptor tyrosine kinases.

SU 4312
20-abx076719
  • EUR 727.20
  • EUR 326.40
  • 25 mg
  • 5 mg

SU 9516
A4467-10 10 mg
EUR 247.2
Description: SU 9516 is a selective and novel inhibitor of CDK2 with IC50 value of 22 nM.

SU 9516
A4467-25 25 mg
EUR 477.6
Description: SU 9516 is a selective and novel inhibitor of CDK2 with IC50 value of 22 nM.

SU 9516
A4467-5 5 mg
EUR 184.8
Description: SU 9516 is a selective and novel inhibitor of CDK2 with IC50 value of 22 nM.

SU 4312
B6746-10 10 mg
EUR 404.4

SU 4312
B6746-5.1 10 mM (in 1mL DMSO)
EUR 254.4

SU 16f
B7354-10 10 mg
EUR 385.2

SU 16f
B7354-5 5 mg
EUR 234

SU 3327
B7444-10 10 mg
EUR 388.8

SU 3327
B7444-50 50 mg
EUR 1453.2

SU 5402
HY-10407 5mg
EUR 176.4